2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2357

Reactions to Online Testimonials: A Cluster Analysis of Risk Perception and Decision Making
Abstract Number: 2358

Risk Factors for Persistent Discordance in Global Assessment of Rheumatoid Arthritis (RA) Disease Activity between RA Patients and Their Physicians: Analysis Based on a Nationwide RA Database (2011 to 2016)
Abstract Number: 2359

Systemic Lupus Erythematous Outcome Concerns: Identifying Pain As the Major Discrepancy between Rheumatologists and Patients
Abstract Number: 2360

Perceptions of Patients with Rheumatoid Arthritis about Self-Assessment of Disease Activity after Watching an Educational Video: Qualitative Pilot Results from the Auto-DAS in Middle Eastern Arab Countries Study
Abstract Number: 2361

Needs, Experiences and Views of People with Rheumatic and Musculoskeletal Diseases about Self-Management Mobile Health Apps: Results of a Mixed Methods Approach
Abstract Number: 2362

Understanding Patients’ Perceptions of Gout
Abstract Number: 2363

Examining Workplace Supports in the Context of RA Disease Activity
Abstract Number: 2364

Vasculitis Patient Journey: A Scoping Review of Patient Experiences with Vasculitis
Abstract Number: 2365

Sex, Language and Age of Disease Onset Impact Illness Perceptions Among RA Patients
Abstract Number: 2366

Facilitating Shared Decision Making in Psoriatic Arthritis: Factors Influencing Patient Preference for Treatment Mode of Administration
Abstract Number: 2367

Acceptance Rate and Sociological Factors Involved in the Switch from Originator to Biosimilar Etanercept (SB4)
Abstract Number: 2368

Patient Preferences for Disease Modifying Anti-Rheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review
Abstract Number: 2369

Patients Preference Goes to MTX Autoinjectors over Prefilled Syringes: Results from a Phase III Trial
Abstract Number: 2370

Physician and Patient Preferences for Treating SLE: Insights into the Choice of Intravenous Infusion and Subcutaneous Injection
Abstract Number: 2371

Use of Social Media Among Patients with Rheumatic Diseases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].